EFFICACY OF PALIVIZUMAB FOR PREVENTING RESPIRATORY SYNCYTIAL VIRUS HOSPITALIZATION IN PRETERM INFANTS: A SYSTEMATIC REVIEW
DOI:
https://doi.org/10.56238/levv17n56-053Keywords:
Respiratory Syncytial Virus Infections, Palivizumab, Infant Premature, HospitalizationAbstract
Introduction: Respiratory syncytial virus remains a leading cause of lower respiratory tract infection and hospitalization among preterm infants worldwide, with significant clinical and economic consequences.
Objective: The main objective was to evaluate the efficacy of palivizumab in preventing respiratory syncytial virus–related hospitalization in preterm infants, with secondary objectives addressing safety, severity reduction, subgroup effects, health system impact, and consistency with current guidelines.
Methods: A systematic search of major biomedical databases was conducted, including PubMed, Scopus, Web of Science, Cochrane Library, LILACS, ClinicalTrials.gov, and ICTRP, following PRISMA recommendations.
Results and Discussion: Twenty studies met the inclusion criteria and were synthesized, demonstrating a consistent reduction in respiratory syncytial virus–related hospitalization among preterm infants receiving palivizumab prophylaxis, although heterogeneity and population-specific effects were observed.
Conclusion: Current evidence supports the continued use of palivizumab in selected preterm infant populations, emphasizing the importance of risk stratification and alignment with updated preventive strategies.
Downloads
References
1 Shi, T., McAllister, D. A., O’Brien, K. L., et al. (2020). Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2019. The Lancet, 396(10252), 946–958.
2 Hall, C. B., Weinberg, G. A., Blumkin, A. K., et al. (2021). Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age. Pediatrics, 147(1), Article e2020017688.
3 Griffin, M. P., Yuan, Y., Takas, T., et al. (2020). Single-dose nirsevimab for prevention of RSV in preterm infants. The New England Journal of Medicine, 383(5), 415–425.
4 American Academy of Pediatrics Committee on Infectious Diseases. (2022). Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of RSV hospitalization. Pediatrics, 150(3), Article e2022057991.
5 Anderson, E. J., DeVincenzo, J. P., & Simões, E. A. F. (2021). Use of monoclonal antibodies for prevention of respiratory syncytial virus disease. Clinical Infectious Diseases, 73(9), e3507–e3515.
6 Simões, E. A. F., Bont, L., Manzoni, P., et al. (2020). Past, present and future approaches to the prevention and treatment of respiratory syncytial virus infection in children. Infectious Diseases and Therapy, 9(1), 87–120.
7 Goldstein, M., Philips, R., Fitzpatrick, T., et al. (2020). Impact of guideline changes on RSV hospitalization rates in preterm infants. The Journal of Pediatrics, 225, 144–150.
8 Resch, B., Kurath, S., & Manzoni, P. (2020). Epidemiology of respiratory syncytial virus infection in preterm infants. The Open Microbiology Journal, 14, 145–154.
9 Rha, B., Curns, A. T., Lively, J. Y., et al. (2024). Respiratory syncytial virus-associated hospitalizations among young children: 2015–2020. Clinical Infectious Diseases, 78(1), 50–58.
10 Farber, H. J., Buckwold, F. J., Lachman, B., et al. (2020). Observed effectiveness of palivizumab for RSV prevention in preterm infants. Pediatric Pulmonology, 55(8), 2031–2038.
11 Anderson, E. J., Krilov, L. R., DeVincenzo, J. P., et al. (2020). Effectiveness of palivizumab in high-risk infants in real-world settings. Journal of the Pediatric Infectious Diseases Society, 9(2), 213–219.
12 Goldstein, M., Philips, R., Fitzpatrick, T., et al. (2020). RSV hospitalizations after restriction of palivizumab prophylaxis. The Journal of Pediatrics, 225, 144–150.
13 Rajah, B., Sánchez-Luna, M., Resch, B., et al. (2021). Palivizumab prophylaxis and intensive care outcomes in preterm infants. The Pediatric Infectious Disease Journal, 40(6), e229–e235.
14 Blake, S. M., Tan, L., McLaurin, K. K., et al. (2021). Seasonal effectiveness of palivizumab in late preterm infants. Clinical Pediatrics, 60(4-5), 212–220.
15 Li, Y., Wang, X., Blau, D. M., et al. (2021). Healthcare utilization and costs associated with palivizumab prophylaxis. PharmacoEconomics, 39(9), 1021–1032.
16 Paes, B., Li, A., Lanctôt, K. L., et al. (2021). Safety and effectiveness of palivizumab in Canadian preterm infants. The Pediatric Infectious Disease Journal, 40(3), e95–e101.
17 Sánchez-Luna, M., Pérez-Muñuzuri, A., Leante-Castellanos, J. L., et al. (2021). Effectiveness of palivizumab in a national registry of preterm infants. European Journal of Pediatrics, 180(8), 2529–2537.
18 Ambrose, C. S., Anderson, E. J., & Simões, E. A. F. (2022). Palivizumab and reduction of severe RSV outcomes in extremely preterm infants. Pediatric Pulmonology, 57(2), 460–468.
19 Griffin, M. P., Krilov, L. R., DeVincenzo, J. P., et al. (2022). Real-world effectiveness of palivizumab in preventing RSV hospitalization. The Journal of Infectious Diseases, 225(4), 706–714.
20 Hampp, C., Kauf, T. L., Saidi, A., et al. (2022). RSV hospitalizations following changes in palivizumab prophylaxis guidelines. Pediatrics, 149(2), Article e2021053758.
21 O’Brien, K. L., Nair, H., Brooks, W. A., et al. (2023). Contemporary evidence on RSV prevention strategies in preterm infants. The Lancet Child & Adolescent Health, 7(3), 195–207.
22 Dagan, R., Madhi, S. A., DeVincenzo, J. P., et al. (2024). Preventing severe RSV disease in high-risk infants: Current evidence and future perspectives. Clinical Infectious Diseases, 78(4), 640–648.
